Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR, Blight AR, on behalf of the MS-F203, MS-F204, and Extension Study Investigators, on behalf of the MS-F203 MS-F204 and Extension Study Investigators